CEL-SCI Reports Fiscal Third Quarter 2026 Results

* Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

* Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term